326 related articles for article (PubMed ID: 27067045)
21. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
[TBL] [Abstract][Full Text] [Related]
22. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules.
Cheng Z; De Jesus OP; Namavari M; De A; Levi J; Webster JM; Zhang R; Lee B; Syud FA; Gambhir SS
J Nucl Med; 2008 May; 49(5):804-13. PubMed ID: 18413392
[TBL] [Abstract][Full Text] [Related]
23. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
24. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
[TBL] [Abstract][Full Text] [Related]
25. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.
Kramer-Marek G; Kiesewetter DO; Capala J
J Nucl Med; 2009 Jul; 50(7):1131-9. PubMed ID: 19525458
[TBL] [Abstract][Full Text] [Related]
26. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
27. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
[TBL] [Abstract][Full Text] [Related]
28. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.
Robinson MK; Doss M; Shaller C; Narayanan D; Marks JD; Adler LP; González Trotter DE; Adams GP
Cancer Res; 2005 Feb; 65(4):1471-8. PubMed ID: 15735035
[TBL] [Abstract][Full Text] [Related]
29. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
[TBL] [Abstract][Full Text] [Related]
30. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
31.
Zettlitz KA; Tavaré R; Tsai WK; Yamada RE; Ha NS; Collins J; van Dam RM; Timmerman JM; Wu AM
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):489-500. PubMed ID: 30456475
[TBL] [Abstract][Full Text] [Related]
32. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.
Paudyal P; Paudyal B; Hanaoka H; Oriuchi N; Iida Y; Yoshioka H; Tominaga H; Watanabe S; Watanabe S; Ishioka NS; Endo K
Cancer Sci; 2010 Apr; 101(4):1045-50. PubMed ID: 20219072
[TBL] [Abstract][Full Text] [Related]
33. Single step 18F-labeling of dimeric cycloRGD for functional PET imaging of tumors in mice.
Li Y; Liu Z; Lozada J; Wong MQ; Lin KS; Yapp D; Perrin DM
Nucl Med Biol; 2013 Nov; 40(8):959-66. PubMed ID: 24090672
[TBL] [Abstract][Full Text] [Related]
34. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.
Kramer-Marek G; Shenoy N; Seidel J; Griffiths GL; Choyke P; Capala J
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1967-76. PubMed ID: 21748382
[TBL] [Abstract][Full Text] [Related]
35. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.
Ren G; Zhang R; Liu Z; Webster JM; Miao Z; Gambhir SS; Syud FA; Cheng Z
J Nucl Med; 2009 Sep; 50(9):1492-9. PubMed ID: 19690041
[TBL] [Abstract][Full Text] [Related]
36. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
[TBL] [Abstract][Full Text] [Related]
37. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
[TBL] [Abstract][Full Text] [Related]
38. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
39. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
40. [
Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]